CSI Frankfurt 2018 - Home


June 27 – 30, 2018
Frankfurt, Germany

CSI Frankfurt 2018: Catheter Interventions in Congenital, Structural and Valvular Heart Disease - CSI 2018 CSI 2018 Catheter Interventions in Congenital, Structural and Valvular Heart Disease
CSI Frankfurt 2018
CSI Frankfurt 2018

Save the Date!
June 27 – 30, 2018 | Frankfurt, Germany
csi pfeil
Newsletter subscription

PodCase
of the Month  
RCA VENOUS BYPASS ANEURYSM
csi pfeil
watch now free of charge

Add to my calendar
CSI 2018 Congress overview Scientific program Focus workshopsImagingInnovationPFOPulmonary valve implantationParavalvar leakMitral valve repair and replacementTAVI
Training hub Abstracts and cases Scientific faculty Attendee information Industry Impressions and references CSI@home Downloads Archive Event calendar Contact
Fontsize bigger
  CSI Frankfurt 2018: Catheter Interventions in Congenital, Structural and Valvular Heart Disease
CSI Frankfurt 2018: Catheter Interventions in Congenital, Structural and Valvular Heart Disease

CSI Focus Innovation - Scientific faculty

Your Faculty access


Board of Directors

Todd Brinton, MD

Stanford University
Stanford
USA

Board of Directors: Todd Brinton, MD
More

Todd Brinton, MD

Stanford University
Stanford, USA

Board of Directors: Todd Brinton, MD
Todd Brinton is a Clinical Associate Professor of Medicine (Cardiology) and Consulting Associate Professor of Bioengineering at Stanford University. He is an attending interventional cardiologist at both Stanford University Medical Center and the Palo Alto VA Medical Center. He has served as the Innovation Fellowship Director for Stanford Biodesign since 2005 and also co-directs the Stanford graduate course series in Biodesign Innovation.

Dr. Brinton lectures on strategies for innovation and serves as a mentor to innovation fellows, graduate students, and executives. His academic research focuses on the process of innovation for development of novel medical technologies. He specifically focuses on the integration of research and development for new technologies with the clinical strategy and pre-clinical evaluation. He has served as a clinical investigator for a number to studies of interventional-based therapies for chronic ischemia heart disease and heart failure.

Dr. Brinton completed his medicine, cardiology, and interventional cardiology training at Stanford University. He holds an MD from the Chicago Medical School and a BS in Bioengineering from the University of California, San Diego. He is Co-Founder and Board Director for Shockwave Medical and BioParadox, Inc., which are both venture-backed medical device companies in the cardiovascular space. He also serves on the board of directors of Qool Therapeutics and Infogard Laboratories. In addition, he serves on the advisory board of a number of early-stage medical device companies, where he focuses on clinical development and strategy. Prior to medical school, he was the Clinical Research Director for Pulse Metric, Inc., a venture-backed medical device start-up company.

Sameer Gafoor, MD

Swedish Heart and Vascular Institute; CardioVascular Center Frankfurt CVC
Seattle
USA

Board of Directors: Sameer  Gafoor, MD
More

Sameer Gafoor, MD

Swedish Heart and Vascular Institute; CardioVascular Center Frankfurt CVC
Seattle, USA

Board of Directors: Sameer  Gafoor, MD
Attending Physician

Dr. Sameer Gafoor is an attending physician at the CardioVascular Center (CVC) Frankfurt headed by Horst Sievert, MD. He obtained his medical degree from Northwestern University in the United States, followed by Internal Medicine Residency at University of michigan. His cardiology training started with Cardiovascular Disease Fellowship at Washington Hospital Center/Georgetown University and continued with Interventional Cardiology Fellowship at Emory University.

Following this training, he went on to complete an Advanced Fellowship in Neurovascular, Coronary, Structural Heart, and Peripheral Vascular Training at the CVC Frankfurt. He specializes in interventions and imaging for structural heart and peripheral vascular disease, as well as development and incorporation of new devices, technologies, and techniques for these and other indications.

Horst Sievert, MD

CardioVascular Center Frankfurt CVC
Frankfurt
Germany

Board of Directors: Horst Sievert, MD
More

Horst Sievert, MD

CardioVascular Center Frankfurt CVC
Frankfurt, Germany

Board of Directors: Horst Sievert, MD
Director and Founder of CVC Frankfurt

Specialist in Internal Medicine, Cardiology, Angiology, and Intensive Care

Medical degree from Johannes Gutenberg University Mainz and Johann Wolfgang Goethe University Frankfurt, Germany

Dr. Sievert has been the Principal Investigator of a number of clinical trials and has authored more than 130 manuscripts and 600 abstracts in peer reviewed journals, as well as 70 books and book contributions. He has also delivered more than 600 invited lectures around the world.
 
He has personally performed more than 16,000 PCIs and 6,000 peripheral angioplasties. However, his activity in the cath lab is focused on highly specialized non-coronary interventions for patients with congenital heart disease, carotid disease, or high risk of stroke, among other conditions. Dr Sievert was the first to close the left atrial appendage percutaneously. He has the largest experience worldwide in catheter closure of heart defects in adults and gets referrals from all over the world.

Co-Directors

Yuval Binur

Arsuf Partners
Tel Aviv, Israel; New York, USA
Shenzhen, China

Co-Directors: Yuval Binur
More

Yuval Binur

Arsuf Partners
Tel Aviv, Israel; New York, USA, Shenzhen, China

Co-Directors: Yuval Binur
Yuval Binur, Ph.D. is a Managing Partner of Orchestra. He has over 29 years of venture capital experience in the United States, Europe and Israel. Dr. Binur is a co-founder of Accelerated Technologies, Inc. and has served as its Chairman of the Board since its inception in 2001. From 1994 until 2004, he was founding Managing Partner of Medica, a global health care and life sciences venture capital fund operating from Israel. In this capacity, Dr. Binur helped raise Medica's first two venture funds and lead the deployment of approximately $140 million in investments into early stage healthcare technology companies. In 2000, he co-founded and led the financing for PVT, an AT I Portfolio company and the pilot for the Orchestra Strategy. In 2001, he co-founded ATI, and in 2003 he began devoting his full time to his role as Chairman of ATI after the Medica II fund was fully invested.

Dr. Binur participated actively in the sourcing, due diligence, deal structuring, investment execution and monitoring of all of the AT I Portfolio companies. He is currently a director of Mitralign, Vital Access and is also a director of SuperDimension, Ltd., a pioneer in the area of interventional pulmonology. For nine years prior to co-founding Medica, Dr Binur was a Member of Adler & Co., a major U.S. venture capital firm based in New York. He has been a board member of 48 venture-backed companies in the areas of medical technology and devices, pharmaceuticals, software and electronics. Dr. Binur holds a B.Sc. degree in electrical engineering from the Technion Institute in Israel and a Ph.D. degree in physics from MIT/Tel Aviv University.

Kathleen Marshall

Maxis Medical LLC
San Jose / Frankfurt
USA / Germany

Co-Directors: Kathleen Marshall
More

Kathleen Marshall

Maxis Medical LLC
San Jose / Frankfurt, USA / Germany

Co-Directors: Kathleen Marshall
Kathleen Marshall created MAXIS, LLC, in 2002 after nearly twenty years as a significant strategic contributor to the overall success of multiple medical device start-up companies. She holds a BA from Amherst College and a MS in Regulatory Affairs from Northeastern University. She is an experienced senior executive, skilled in clinical research, market development and commercialization of new medical technology. During her career in medical device start-ups, she has established a proven track record in conducting international clinical studies, building global markets, branding emerging technologies and leading start-up ventures. She has successfully established and managed teams that have created lasting clinical value and financial returns. She holds dual citizenship in the USA and Ireland.

Holly Whitin, MD

Maxis Medical
San Jose / Frankfurt am Main
USA / Germany

Co-Directors: Holly Whitin, MD
More

Holly Whitin, MD

Maxis Medical
San Jose / Frankfurt am Main, USA / Germany

Co-Directors: Holly Whitin, MD
Holly Whitin has more than 30 years’ experience in the market development and launch of innovative technologies in interventional cardiology and structural heart disease, including two transformational and disruptive platforms: angioplasty and transcatheter aortic valves. Her primary focus has been on Europe and Asia. She has been fundamental in bringing KOL advisory boards together and building multidisciplinary teams to accelerate clinical trial enrollment, efficient resource utilization and market adoption. Holly holds a BA from Swarthmore College and an MBA from the Darden School (U.Va.) She has worked in the medical device & pharmaceutical industry since the 1980’s. Ms. Whitin is a U.S. citizen and currently resides in Switzerland. She is fluent in English and French and is conversational in German. She has lived in several other countries, including The Netherlands, Belgium, Germany and Japan.

Faculty

Susan Alpert

SFA Consulting, LLC
Minneapolis
United States of America

Faculty: Susan Alpert

Jeffrey A. Anderson

REVA Medical, Inc.
San Diego
USA

Faculty: Jeffrey A. Anderson

Martin Bocks, MD

UH Rainbow Babies and Children's Hospital
Cleveland
USA

Faculty: Martin Bocks, MD
More

Martin Bocks, MD

UH Rainbow Babies and Children's Hospital
Cleveland, USA

Faculty: Martin Bocks, MD
Residency
  • since 2004, University of Michigan (U of M) Adult Congenital Heart Disease Program, Cardiovascular Center, Ann Arbor, MI, USA
  • since 2004, University of Michigan (U of M) Pediatric Cardiology, C.S. Mott Children's Hospital, Ann Arbor, MI, USA

Specialties
  • Pediatric Cardiology
  • Adult Congenital Heart

Clinical Interests
  • Interventional Cardiology
  • Pediatric and Adult Interventional Cardiac Catheterization
  • Adult Congenital Heart Disease

Medical School
  • Wayne State University School of Medicine, 2000

Fellowship
  • Pediatric Cardiology, University of Michigan Health System, 2007
  • Pediatric Interventional Cardiac Catheterization, University of Michigan Health System, 2008

Professional Organizations

  • American Heart Association
  • Alpha Omega Alpha
  • Fellow, American College of Cardiology
  • Member, Society for Cardiovascular Angiography and Interventions
  • Member, American Society for Artificial Internal Organs

Board Certification

  • Pediatric Cardiology
  • Internal Medicine

Dr. Bocks’ research focuses mainly on medical device development. His primary device project is on developing an implantable cardiac pressure sensor to monitor the ambulatory pulmonary artery pressure in functional single ventricles patients following Fontan operation. In addition, Dr. Bocks is involved in a multidisciplinary team to use novel bioresorbable materials to develop devices for use in pediatric atrial septal defect closure and stent implantation. He is an investigator within the University of Michigan Extracorporeal Life Support Research Laboratory and is involved in numerous ongoing projects in the lab.

Dr. Bocks continues to lead a prospective longitudinal study to characterize aspirin responsiveness in the congenital heart disease population with the goal to determine if a simple blood test can accurately predict which patients are at increased risk for abnormal blood clot formation. Finally, Dr. Bocks participates in numerous clinical research projects involving interventional cardiac catheterization procedures performed at the University of Michigan.

Laurence Fiette, MD

Institut Mutualiste Montsouris
Paris
France

Faculty: Laurence Fiette, MD
More

Laurence Fiette, MD

Institut Mutualiste Montsouris
Paris, France

Faculty: Laurence Fiette, MD
Dr Laurence Fiette is a veterinary pathologist specialized in biomedical devices. She graduated and did her
residency in Veterinary Pathology at the Veterinary school of Alfort, and did her PhD at the Institut Pasteur, Paris.
She has more than 25 years of experience in animal models in academic research (Institut Pasteur, Paris and
Faculty of Medicine, Geneva, Switzerland). After 10 years as a consultant, she is now Head of Pathology at the
IMMR, a CRO that committed to be one of the world-leader centres of expertise in preclinical testing of medical
devices and research projects in large animal models.

Aloke Virmani Finn, MD

CVPath Institute Inc.
Gaithersburg
USA

Faculty: Aloke Virmani Finn, MD

Carlos Granada

Clinlogix
Ambler
USA

Faculty: Carlos Granada

Jeffrey Jump

Med Alliance SA
Rolle
Switzerland

Faculty: Jeffrey Jump

Alex Khairkhakan

Polares Medical
Palo Alto
USA

Faculty: Alex Khairkhakan
More

Alex Khairkhakan

Polares Medical
Palo Alto, USA

Faculty: Alex Khairkhakan
Mr. Khairkhahan is founder and COO of Middle Peak Medical, with over 25 years of medical device experience. Most recently he was a founding member at Nanostim, where he led development of a leadless pacemaker.

Prior to Nanostim, Mr. Khairkhahan founded CardioKinetix where he developed an LV implant (Parachute) for treatment of CHF. At Appriva, he had a leadership role in developing PLAATO, the left atrial appendage occlusion device.

Prior to Appriva, he held management positions at Danforth Biomedical, Micrus, and MDT.

Mr. Khairkhahan received his BS and MS degrees in Mechanical Engineering from Northeastern University.

Alex is the proprietor of Vquad Medical Inc., which is a medical device incubator and is named inventor on more than 100 patents.

Michael Lauk

neuroloop GmbH
Freiburg
Germany

Faculty: Michael Lauk
More

Michael Lauk

neuroloop GmbH
Freiburg, Germany

Faculty: Michael Lauk
Michael Lauk is a serial start-up entrepreneur in the healthcare field, focused on medical devices. He has more than 25 years of experience in business as well as research in the healthcare field in Germany and the USA. Most recently he co-founded neuroloop GmbH, a Start-up designing an active implantable device to lower blood-pressure. Besides neuroloop, he co-founded the start-ups SpinDiag GmbH, Tomes GmbH, inSleep Health LLC, resp(EQ) Inc., TNI medical AG and seleon GmbH, where he worked in different management and board positions.
Michael earned his PhD in physics in Freiburg and Boston. He is a data scientist and an early mover in the Digital Health arena, and seasoned in designing healthcare products and marketing strategies. He has executed more than 50 medical device projects, and initiated several co-operations between companies, hospitals, and universities.

Martin B. Leon, MD

Columbia University Medical Center
New York, NY
USA

Faculty: Martin B. Leon, MD
More

Martin B. Leon, MD

Columbia University Medical Center
New York, NY, USA

Faculty: Martin B. Leon, MD
Director, Center for Interventional Vascular Therapy, Columbia University Medical Center / New York-Presbyterian Hospital 

Positions and Appointments  
  • Since 2010 Director, Center for Interventional Vascular Therapy, Columbia University Medical Center/New York-Presbyterian Hospital, New York
  • Since 2004 Professor of Medicine, Columbia University College of Physicians and Surgeons New York

Clinical Specialties
  • Interventional Cardiologist
  • Structural and Valvular Specialist

Education and Training
  • 1983 - 1985 Senior Investigator, National Institutes of Health, NHLBI Cardiology Section, Bethesda, Maryland    
  • 1980 - 1982 Fellow, Cardiology, Yale University School of Medicine, New Haven, Connecticut  
  • 1978 - 1980 Clinical Associate, National Institutes of Health, NHLBI Cardiology Section, Bethesda, Maryland    
  • 1976 - 1978 Resident, Internal Medicine, Yale University School of Medicine,New Haven, Connecticut  
  • 1975 – 1976 Intern, Internal Medicine, Yale University School of Medicine, New Haven, Connecticut  
  • 1971 - 1975 Doctor of Medicine, Yale University School of Medicine, New Haven, Connecticut

Board Certifications
  • American Board of Internal Medicine
  • ABIM, Cardiology
  • ABIM, Interventional Cardiology


Dr. Martin B. Leon, M.D., also known as Marty, Co-Founded TriVentures. Dr. Leon serves as Medical Advisor at Vascular Closure Systems, Inc. He served as Scientific Advisor of OrbusNeich Co., Ltd. (now Orbus Medical Technologies, Inc.). He is the Chairman Emeritus, President and Chief Executive Officer of the Cardiovascular Research Foundation and Senior Attending Physician at the Lenox Hill Heart and Vascular Institute of New York.

He is a practicing interventional cardiologist at New York-Presbyterian Hospital/CUMC. Dr. Leon serves as Chief Executive Officer of Cardiovascular Research and Education, Lenox Hill Hospital, New York, NY. He serves as Clinical Professor of Medicine at Georgetown University Medical Center in Washington.

He co-founded Accelerated Technologies, Inc. in 2001. Dr. Leon founded Clinsights, Inc. He served as the Chief Scientific Officer of Vascular Reconditioning Inc. Dr. Leon served as a Clinical Associate, Senior Investigator, and Director of the Catheterization Laboratories in the Cardiology Branch of the National Heart, Lung and Blood Institute at the National Institutes of Health in Bethesda, Maryland.

Dr. Leon was a founder of the Washington Cardiology Center and the Cardiology Research Foundation in Washington, DC. In 1990, he joined a group of interventional cardiologists to form the Washington Cardiology Center and Cardiovascular Research Foundation. Dr. Leon serves as the Chairman of Medical Advisory Board at MediVas, LLC and Angioscore, Inc. He served as the Chairman and Member of Medical Advisory Board at Biopure Corp. Leon serves as a Member of Scientific Advisory Board at Orbus Medical Technologies, Inc. He has been a Member of Clinical Advisory Board at MIV Therapeutics Inc. since March 2008. He serves as a Director of Cappella Inc. He serves as a Member of Advisory Board at InspireMD Ltd. and Percardia, Inc. Dr. Leon serves as a Member of Scientific Board at MediGuide Ltd. He serves as a Member of Scientific Advisory Board at CardiAQ Valve Technologies, Inc., Gardia Medical Ltd., Corindus, Inc. Cappella Inc. and Sahajanand Medical Technologies Pvt. Ltd. He serves as a Member of Advisory Board at Paieon, Inc. He serves as Member of Medical Advisory Board at E.K.Guard Inc., Caliber Therapeutics, Inc., X-Cell Medical, Inc., Coherex Medical, Inc. and Angioscore, Inc. Dr. Leon serves as a Member of Scientific Advisory Board at XTENT, Inc., Conor Medsystems, LLC, and Stereotaxis Inc. He serves as Member of Clinical and Scientific Advisory Board at FlowMedica, Inc.

He serves as a Director of Clinical Research at the Washington Cardiology Center at the Washington Hospital Center. He served as Member of Clinical Advisory Board of ITGI Medical Ltd. He served as a Member of Cardiac Advisory Board of Cytori Therapeutics, Inc. since May 2006.

Dr. Leon is as a Founder and Director of Transcatheter Cardiovascular Therapeutics at Columbia University Medical Center. He serves as a Member of Advisory Board at InspireMD, Inc. He served as a Director of Clinsights, Inc., which Founded. Dr. Leon served as a Member of Scientific Advisory Board at Light Sciences Corporation. He served as a Member of Medical Advisory Board at Mitralign, Inc. and Neovasc Inc. He served as a Member of Scientific Advisory Board at Prescient Medical, Inc. He served as a Member of the Board of Directors of Angiosonics.

Dr. Leon serves as Chairman Emeritus of the Cardiovascular Research Foundation. He also served as Chairman and Director of Cardiovascular Research Foundation.

Dr. Leon has co-authored over 1500 publications, has performed over 10,000 interventional procedures, and has been intimately involved in a wide range of interventional vascular therapy activities, including vascular stents, new device angioplasty with atherectomy and laser techniques, intravascular ultrasound, direct myocardial revascularization, and angiogenesis.

He is a Professor of Medicine at Columbia University Medical Center (CUMC). Dr. Leon is an Associate Director of Center for Interventional Vascular Therapy, Cardiovascular Interventional Therapy of Columbia University Medical Center.

He served as Member of Scientific & Regulatory Advisory Board at 3D Communications Inc.

Dr. Leon completed graduate of medical school at the Yale School of Medicine, where he also completed formal training in internal medicine and cardiology and his internship and residency in internal medicine at the Yale-New Haven Hospital. He completed a fellowship in Cardiology at the Yale-New Haven Hospital. Dr. Leon received his BSc from the State University of New York and his MD from Yale University School of Medicine.

Florian Ludwig

Thuja Capital
Utrecht
Netherlands

Faculty: Florian Ludwig
More

Florian Ludwig

Thuja Capital
Utrecht, Netherlands

Faculty: Florian Ludwig
Florian Ludwig, Ph.D.

Thuja Capital Management, Utrecht, The Netherlands

Florian Ludwig, Ph.D., is a seasoned medical device professional, with 15+ years experience in the development of medical devices, including product, clinical and market development, and an intimate understanding of combination devices. He has led and served on innovation and development teams in global organizations (Guidant, Abbott Vascular, Covidien) and in start-ups (Ventrigraft, Ventrica, ROX Medical, Direct Flow Medical). Drawing on a combination of scientific understanding, market insight and direct field experience, Florian has provided leadership to innovative therapy development programs for heart failure, structural heart, cardiovascular, pulmonary and orthopedic indications.
In 2016, Florian joined the management team of Thuja Capital Management (“Thuja”), a European venture capital fund focused on early stage healthcare investments. Thuja has currently over €50 million under management, with active investments in medtech, biotech and nutraceuticals.
Florian holds a Diplom and a doctorate degree in physics from the Technical University of Munich, Germany, gained in research collaborations with Duke University, USA, and the University of British Columbia, Canada. He is an author on over 40 issued patents.

Georg Matheis

Xenios AG
Heilbronn
Germany

Faculty: Georg Matheis
More

Georg Matheis

Xenios AG
Heilbronn, Germany

Faculty: Georg Matheis
Georg Matheis cofounded Novalung  and has served as the company’s managing director since its inception in 2003. He also manages  Xenios AG, a technology holding for heart and lung assist devices. Georg has 30 years of clinical, academic and entrepreneurial experience in the medical device and biotech sectors.

He cofounded, managed, and invested in several medical device and biotech companies, and served in clinical and academic positions at Goethe University in Frankfurt as a cardiac surgeon.  

Georg Matheis holds Dr. med. (summa cum laude) and Privatdozent degrees from Goethe University at Frankfurt, and a Prof. h.c. from FAMEMA Marilia, Sao Paulo. His academic career includes positions at UCLA, Freiburg University and Goethe University in Frankfurt.

Apart from his entrepreneurial role he is a distinguished speaker, lecturer, and editor, and is the author of numerous peer-reviewed scientific articles.

Ian T. Meredith

Boston Scientific
Marlborough
USA

Faculty: Ian T. Meredith

Anthony Nobles

HeartStitch, Inc.
Fountain Valley
USA

Faculty: Anthony Nobles
More

Anthony Nobles

HeartStitch, Inc.
Fountain Valley, USA

Faculty: Anthony Nobles
Chairman of The Board & CEO of HeartStitch, Inc.

Anthony Nobles is a medical professional, engineer, inventor, entrepreneur, professor and philanthropist. Over the past 28 years, he has developed and patented more than 150 products and medical devices. He specializes in vascular and cardiovascular devices, and his inventions have assisted surgeons around the world in successfully performing complex suturing and cardiac surgeries.

Nobles has founded several medical technology companies and currently serves as the Chairman and CEO of HeartStitch Medical, Inc. and Nobles Medical Technologies II, Inc. One of his earlier business ventures, Nobles Medical Technologies I, was sold to Medtronic in 2010. He also founded Sutura, which he took public in 2005.

Professor Nobles currently holds over 40 patents and has been a contributing author for various medical publications on a variety of surgical topics. He travels all over the world training surgeons and physicians in the procedures he has personally developed. With over 28 years of clinical and operating room experience, he is recognized worldwide as an expert in his field.

His career successes have afforded him the ability to make considerable contributions to charities and local community initiatives. The Nobles Family helped to fund the Sunset Beach Community Center, which was renamed the Nobles Family Community Building in appreciation for their efforts. Professor Nobles also delights local residents by organizing and personally funding an elaborate Halloween extravaganza that has attracted 30,000 in the past.

Outside of his professional and philanthropic efforts, Professor Nobles is an avid car enthusiast and Formula 1 race car driver.

Prof. Nobles has invented over 150 medical devices and holds multiple patents and trademarks for technologies from electronics and medical devices to automotive technologies. Prof. Nobles has lectured and presented around the world at the American college of Cardiology, the Society of vascular Surgery, the American College of Neurosurgery, Congress on Congenital & Structural Interventions, Paris meeting on Revascularizations, Harvard Medical School, USC School of Healthcare, UCLA Medical School, University of Zwickau and many other congresses and schools. Prof. Nobles recently became a Professor of Biomedical Science at the West Sachsen University Zwickau, Germany.

Tor Peters

Occlutech®
Helsingborg
Sweden

Faculty: Tor Peters
More

Tor Peters

Occlutech®
Helsingborg, Sweden

Faculty: Tor Peters
Education
  • BSc Business Administration & Marketing, Lund University, Sweden, 1981-1984
  • MBA, IMD/IMI Geneva 1997-1988

Professional Experience
  • Global Product Manager, Viggo AB / BOC Health Care, Sweden, 1984-1987
  • Global Marketing Manager Devices, Novo Nordisk, Copenhagen Denmark, 1988-1990
  • Sales Manager, Novo Nordisk, Germany, 1990 - 1992
  • Marketing Manager Europe, Scimed/Boston Scientific, Munich/Dusseldorf, 1993-1995
  • Co-founder & CEO, JOMED Group, 1996 – 2003
  • Co-founder of Millimed Inc. 2003
  • Founder of NOLabs AB 2004 –
  • Chairman & Shareholder - Occlutech GmbH 2005 –
  • CEO Occlutech Holding AG 2009 –
  • Chairman of the board Synergio AB, Lund Sweden 2013 –
  • Non-executve board member SIC Invent AG, Basel Switzerland 2011 –
  • Non-executive board member of PI Harvest Holding AG, Schaffhausen Switzerland 2011 –

Santosh Prabhu

Abbott Structural Heart
Menlo Park
USA

Faculty: Santosh Prabhu

Stan Rabinovich

Edwards Lifesciences Corp.
Irvine
USA

Faculty: Stan Rabinovich
More

Stan Rabinovich

Edwards Lifesciences Corp.
Irvine, USA

Faculty: Stan Rabinovich
Stan Rabinovich currently serves as Vice President, Advanced Technology at Edwards Lifesciences. He joined the company in 2004 when Edwards acquired Percutaneous Valve Technologies, Inc. (PVT), of which he was co-founder, Executive Vice President and COO.  PVT has pioneered the development of transcatheter heart valves.

Stan spent over 17 years of his medical device development career at Johnson & Johnson, where he held positions in Engineering, R&D and Business Development at Johnson & Johnson Interventional Systems (JJIS), SITE Microsurgical and Johnson & Johnson Ultrasound.

Stan graduated from Riga Polytechnic Institute, Latvia and holds a Master’s degree in Electrical Engineering.

Trent Reutiman

Mercator MedSystems, Inc.
Emeryville
USA

Faculty: Trent Reutiman

Benjamin Rieck

Angio Consult GmbH
Speyer
Germany

Faculty: Benjamin Rieck

James Roberts III




Faculty: James Roberts III

Thomas Seeger

Medalliance GmbH
Auggen
Germany

Faculty: Thomas Seeger

Rick Shoop




Faculty: Rick Shoop

Ron Solar

ThermopeutiX, Inc.
San Diego
USA

Faculty: Ron Solar
More

Ron Solar

ThermopeutiX, Inc.
San Diego, USA

Faculty: Ron Solar
Dr. Ronald Solar received his Ph.D. in Biomaterials and Materials Science from the University of Pennsylvania, and has been designing and developing medical devices for over 40 years. He co-founded a number of successful medical device companies, played key roles in the successful launch of others, and currently holds over 50 patents. In 1989, Dr. Solar was recognized by President George Bush as one of the Ten Outstanding Young Americans, and JCI selected him as one of the Ten Outstanding Young People of the World for his contributions in medical innovation. His current research interests include vascular injury, local drug delivery, and selective hypothermia as a means to treat stroke and other cerebral ischemic injury.

Karl von Mangoldt

Protembis GmbH
Aachen
Germany

Faculty: Karl von Mangoldt
CSI   CSI
Contact Data Privacy Imprint Home Visit us on Facebook Visit us on Twitter